ArticleBMC rheumatology2018

A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis.

Annemarie Schorpion et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.